Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.

摘要: Potent and specific, or relatively inhibitors of epidermal growth factor receptor (EGFR) signaling, including monoclonal antibodies small molecular weight compounds, have been successfully developed. Both types agent found to significant antitumor activity, especially when used in combination with radio- hormone- chemotherapy preclinical studies. Because the potentiation conventional drug activity these settings, EGFR signaling often referred as sensitizers for radiation, well resistance reversal agents. Phase II clinical trials head-and-neck lung cancer suggested this concept chemosensitization might translate into clinic, but remains be definitively proven randomized, double-blind III trials. Given extensive literature on blocking drugs advanced development such agents, it is surprising that possibility acquired themselves, a common problem virtually all other currently anticancer drugs, largely unexplored subject investigation. Here we summarize some possible mechanisms can result EGFR-targeting drugs. Alternative therapies circumvent delay are suggested.